Study of INBRX-109 in Conventional Chondrosarcoma

This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

In order to participate you must meet the following criteria:

• Have conventional chondrosarcoma that is unresectable (=inoperable) or metastatic.
• Have radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to screening for this study.
• Have adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
• Have estimated life expectancy of at least 12 weeks.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.